Recent advances in understanding proteasome function

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 5, 1999, Pages 484-490

  Eiott, Peter J ^a   Adams, Julian ^a  

^a ProScript Inc   (United States)

Author keywords

Bcl 2; Cancer; Inflammation; Inhibitor; Lactacystin; NF B; p53

Indexed keywords

5 METHOXY 1 INDANONE 3 ACETYL LEUCYL DEXTRO LEUCYL 1 INDANYLAMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CEP 1612; IRINOTECAN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; RITONAVIR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BRAIN ISCHEMIA; COLON CANCER; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 0032741593     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. An B, Goldfarb RH, Siman R, Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Ce Death Differentiation (1998) 5:1062-1075.
2. Herrmann JL, Briones F, Brisbay S, Logothetis CJ, McDonne TJ: Prostate carcinoma ce death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene (1998) 17:2889-2899.
3. Lum RT, Kerwar SS, Meyer SM, Nelson MG, Schow SR, Shiftman D, Wick MM, Joly A: A new structural class of proteasome inhibitors that prevent NF-icB activation. Biochem Pharmacol (1998) 55:1391-1397.
4. Lum RT, Nelson MG, Joly A, Horsma AG, Lee G, Meyer SM, Wick MM, Schow SR: Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5methoxy-1-indanone dipeptide benzamides. Bioorg Med Chem Lett (1998) 8:209-214.
5. Lynas JF, Harriott P, Healy A, McKervey MA, Walker B: Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl a-keto aldehydes (Glyoxals). Bioorg Med Chem Lett (1998) 8:373-378.
6. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma Y-T, Plamondon L, Stein RL: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 8:333-338.
7. André P, Groettrup M, Klenerman P, De Giuli R, Booth BL, Cerundolo V, Bonnevie M, Jotereau F, Zinkemagel RM, Lotteau V: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T ce responses. Proc NatlAcadSci USA (1998) 95:13120-13124.
8. Loidl G, Gro M, Musiol H-J, Huber R, Moroder L: Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sei USA (1999) 96:5418-5422.
9. Corey EJ, Li W-D, Nagamitsu T, Fenteany G: The structural requirements for inhibition of proteasome function by the lactacystin-derived -lactone and synthetic analogs. Tetrahedron (1999) 55:3305-3316.
10. Ponnappan U, Zhong M, Trebilcock GU: Decreased proteasomemediated degradation in T ces from the elderly: a role in immune senescence. Ce/llmmuno/(1999) 192:167-174.
11. Schwartz O, Maréchal V, Friguet B, Arenzana-Seisdedos F, Heard J-M: Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol (1998)72:3845-3850.
12. Palombea VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Eiott PJ, Lazarus DD, McCormack TA, Parent L, Stein R, Adams J, Grisham MB: Role of the proteasome and NF-x-B in streptococcal ce wa-induced polyarthritis. Proc Natl Acad Sei USA (1998) 95:15671-15676.
13. Vandertugt CL, Rahbe SM, Eiott PJ, Dal Cantro MC, Mier SD: Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Neuroimmunol (1999) in press.
14. Eiott PJ, Pien CS, McCormack TA, Chapman ID, Adams J: Proteasome inhibition: A novel mechanism to combat asthma. J Aergy Clin Immunol (1999) 104:1-7.
15. Campbe B, Adams J, Shin YK, Lefer AM: Cardioprotective effects of a novel proteasome inhibitor foowing ischemia and reperfusion in the isolated perfused rat heart. J Mol
16. Ce Cardiol (1999) 31 -.467-476. •• Demonstrates that proteasome inhibitors reduce neutrophil invasion of ischémie cardiac tissue and improve cardiac function.
17. Phiips JB, Wiiams AJ, Adams J, Eiott PJ, Tortea FC: The proteasome inhibitor, PS-519 reduces infarction in a rat model of cerebral ischemia. Proc Nail Acad Sei USA (1999) submitted for publication.
18. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, Tanaka K: The proteasome is involved in angiogenesis. Biochem Biophys Res (1998) 246:243-248.
19. Adams J, Palombea VJ, Sausvie EA, Johnson J, Destree A, Lazarus DD, Mass J, Pien CS, Prakash S, Eiott PJ: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res (1999) 59:2615-2622.
20. Wang C-Y, Cusack JC. Liu R, Baldwin AS: Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-xB. Nature Med (1999) 5:412-417.
21. Desai SD, u'u LF, Vazquez-Abad D, D'Arpa P: Ubiquitindependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem (1997) 272:24159-24164.
22. Lin ZP, Boiler YC, Amer SM, Russe RL, Pacei KA, Patiemo SR, Kennedy KA: Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG132: Involvement of NF-icB activation in drug resistance. Cancer Res (1998) 58:3059-3065.
23. Ortowski RZ, Eswara JR. Lafond-Walker A, Grever MR, Orlowski M, Dang CV: Tumor growth inhibition induced in a murine model of human Burkirt's lymphoma by a proteasome inhibitor. Cancer Res (1998) 58:4342-4348.
24. Honda T, Yasutake K, Nihonmatsu N, Mercken M, Takahashi H, Murayama O, Murayama M, Sato K, Omori A, Tsubuki S, Saido TC, Takashima A: Dual roles of proteasome in the metabolism of presenilin 1. J Neurochem (1999) 72:255-261. • Suggests a role of the proteasome in the development of Alzheimer's disease through altered metabolism of presenilin 1.